“We believe that PK-focused clinical approaches have the potential to reshape biosimilar development in a lasting way,” says Dr Andreas Seidl, CSO of Formycon: lnkd.in/ebzuA4vD

Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year formycon.com/en/investor-rel…

Formycon invites to conference call on 2026 half-year results: webcast-eqs.com/formycon-202…

In the #NebenwerteWelt podcast, Formycon CFO Enno Spillner shares insights on the basics of #biosimilars and what makes the dynamic biosimilar market so attractive youtu.be/xWkjpQK9FOI?si=BLJ4…

Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026 formycon.com/en/blog/press-r…

Formycon invites to conference call on the results of the first quarter of 2026. The conference call will take place on Thursday, May 28, 2026, at 3:00 PM (CEST) in English: webcast-eqs.com/formycon-202…

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧’𝐬 𝐚𝐟𝐥𝐢𝐛𝐞𝐫𝐜𝐞𝐩𝐭 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞: formycon.com/en/blog/press-r…

For information on the 2025 financial results and the outlook for 2026, please refer to our corporate news: formycon.com/en/blog/press-r… For full details on the financial results, please refer to the Annual Report on our website: formycon.com/wp-content/uplo…

𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐂𝐚𝐥𝐥 𝐨𝐧 𝐭𝐡𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐅𝐢𝐬𝐜𝐚𝐥 𝐘𝐞𝐚𝐫 To follow the conference live, please register via the following link: webcast-eqs.com/formycon-202… Access the replay at: formycon.com/en/investor-rel…

The European Biotechnology Science & Industry Guide is more than just a “Who's Who” of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐞𝐜𝐮𝐫𝐞𝐬 𝐥𝐢𝐜𝐞𝐧𝐬𝐞 𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐅𝐘𝐁𝟐𝟎𝟑 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 𝐚𝐧𝐝 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐭𝐞𝐫𝐫𝐢𝐭𝐨𝐫𝐢𝐞𝐬 Market launches by commercialization partners across Europe to start in May 2026 formycon.com/en/blog/press-r…

🔬 Dahlia study demonstrates PK equivalence of FYB206 with the reference drug Keytruda® formycon.com/en/blog/press-r…

We are happy to announce another milestone in our global commercialization journey for FYB206: formycon.com/en/blog/press-r…

The FDA has approved Nufymco®, another interchangeable #ranibizumab #biosimilar in the U.S., underscoring Formycon’s pioneering position in high-quality biosimilar #development: formycon.com/en/blog/press-r…

Zydus Lifesciences Limited to commercialize Formycon’s Keytruda biosimilar FYB206 in the US and Canada: formycon.com/en/blog/press-r…

Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytruda® biosimilar candidate in the #MENA region: formycon.com/en/blog/press-r…

Immunological Dupilumab Biosimilar Candidate FYB208 as another growth driver in Formycon's portfolio formycon.com/en/blog/press-r…

#WorldPsoriasisDay Psoriatic Disease and Comorbidities - Early Diagnosis and proper Treatment save Lives formycon.com/en/blog/2025/10…

Formycon sets a new standard: FYB201/Ranivisio®is the first ranibizumab biosimilar on the European market in a pre-filled syringe presentation For more information, please check our press release at: formycon.com/en/blog/press-r…